Core Viewpoint - Pfizer emphasizes its commitment to innovation and accessibility in the Chinese market, aligning with national policies to enhance the availability of innovative drugs for patients [1][2]. Group 1: Policy Support for Innovative Drugs - The Chinese government has intensified efforts to create a supportive policy framework for innovative drug development, including measures to integrate innovative drugs into basic medical insurance and commercial health insurance [2]. - Recent policies from both central and local governments have established a timeline and guarantees for the accessibility and affordability of innovative drugs, reflecting China's transition from a "big pharmaceutical country" to a "strong pharmaceutical country" [2]. Group 2: Pfizer's Initiatives at the Expo - Pfizer will host the "Innovation Access Summit" for the fifth consecutive year at the expo, aiming to explore market access and payment innovation for breakthrough drugs through collaboration with various stakeholders [3]. - The company plans to sign a donation agreement for an innovative hemophilia drug, marking the first drug donation project under the "pilot" policy, which will provide sustainable experiences for future initiatives [3]. Group 3: Pfizer's Market Presence and Achievements - Over its 36 years in China, Pfizer has introduced more than 80 innovative products across key therapeutic areas, including inflammation and immunity, oncology, vaccines, and migraines, ensuring that Chinese patients benefit from cutting-edge medical solutions [3]. - By 2025, Pfizer has successfully launched nine innovative drugs in Hainan Boao Lecheng, three in the Guangdong-Hong Kong-Macao Greater Bay Area, and one in the Tianjin Free Trade Zone, alongside multiple real-world research projects [3].